Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Midodrine and Albumin for Cirrhotic Patients With Functional Renal Impairment (MAFRI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01133795
Recruitment Status : Completed
First Posted : May 31, 2010
Last Update Posted : August 18, 2016
Information provided by (Responsible Party):
Pere Gines, Hospital Clinic of Barcelona

Brief Summary:
The objective of the study was evaluate the effect of administration of midodrine and albumin on renal function in patients with cirrhosis and creatinine greater than 1,2mg/dl.

Condition or disease Intervention/treatment Phase
Cirrhosis Renal Failure Drug: Midodrine plus Albumin Phase 2

Detailed Description:
Twenty patients with cirrhosis and functional renal impairment, defined by a serum creatinine greater than 1,2mg/dl, will be included. Patients will receive daily midodrine at a dose of 10mg tid and 40g of albumin at 15-day interval. The follow-up period will be of 12 weeks. In all patients, liver and renal function, and vasoactive hormones (plasma renin activity, aldosterone, noradrenaline, ADH, endothelin and anf)will be determined at baseline conditions. At this moment, glomerular filtration rate and renal plasma flow determined by isotopic techniques as ambulatory blood pressure monitoring through a 24-hour period will be performed too. All these determinations will be repeated at 4 and 12 weeks. During the study period, just before the albumin infusions, blood will be drawn for creatinine and electrolytes determinations and these will be recorded as well physical examination performed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Administration of Intravenous Albumin and Oral Midodrine on Renal Function in Patients With Cirrhosis and Functional Renal Impairment
Study Start Date : February 2010
Actual Primary Completion Date : June 2016
Actual Study Completion Date : June 2016

Arm Intervention/treatment
Experimental: Midodrine, Albumin
Midodrine 10mg tid for 12 weeks. Albumin 40g every 14 days for 12 weeks
Drug: Midodrine plus Albumin
MIdodrine 10mg tid for 12 weeks. Albumin 40g every 14 days for 12 weeks
Other Names:
  • Albumin Grifols
  • Gutron

Primary Outcome Measures :
  1. Changes in glomerular filtration rate assessed by isotopic methods [ Time Frame: at 12 weeks of treatment ]

Secondary Outcome Measures :
  1. changes in arterial pressure as assessed by continuous ambulatory arterial pressure [ Time Frame: at 12 weeks of treatment ]
  2. changes in plasma renin activity [ Time Frame: at 12 weeks of treatment ]
  3. changes in aldosterone concentration [ Time Frame: at 12 weeks of treatment ]
  4. changes in norepinephrine concentration [ Time Frame: at 12 weeks of treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Liver Cirrhosis
  • Serum Creatinine greater than 1,2 mg/dL
  • to have given written informed consent

Exclusion Criteria:

  • pregnancy
  • Systolic blood pressure above 150mmHg and/or diastolic blood pressure above 90mmHg
  • Previous treatment with transjugular intrahepatic portosystemic shunt (TIPS) or surgical shunts
  • Antibiotic treatment in the previous 7 days before inclusion, except for prophylaxis of spontaneous bacterial peritonitis
  • infection by HIV
  • contraindications for albumin and/or midodrine use

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01133795

Layout table for location information
Hospital Clinic
Villarroel 170,Barcelona, Barcelona, Spain, 08036
Sponsors and Collaborators
Hospital Clinic of Barcelona
Layout table for investigator information
Principal Investigator: Pere Ginès, MD Hospital Clinic of Barcelona

Layout table for additonal information
Responsible Party: Pere Gines, chief of hepatology unit, Hospital Clinic of Barcelona Identifier: NCT01133795    
Other Study ID Numbers: MAFRI
First Posted: May 31, 2010    Key Record Dates
Last Update Posted: August 18, 2016
Last Verified: August 2016
Keywords provided by Pere Gines, Hospital Clinic of Barcelona:
renal failure
hepatorenal syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Cirrhosis
Renal Insufficiency
Pathologic Processes
Liver Diseases
Digestive System Diseases
Kidney Diseases
Urologic Diseases
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Vasoconstrictor Agents
Adrenergic alpha-1 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action